HSBC analyst Rajesh Kumar raised the firm’s price target on GSK (GSK) to 1,500 GBp from 1,200 GBp and keeps a Reduce rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, “even more so if AI panic kicks in.” HSBC’s preferred stocks are “growth bucket ideas,” but says “fallen angels and value could work as well.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Ideaya disclosed termination of GSK license agreement
- GSK price target raised to 1,700 GBp from 1,500 GBp at JPMorgan
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports